71
6
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T9407 |
Rasarfin
|
Others; Ras | GPCR/G Protein; MAPK; Others |
Rasarfin 是Ras 和ARF6双抑制剂。 | |||
T41256 |
SP-96
|
Aurora Kinase | Cell Cycle/Checkpoint; Chromatin/Epigenetic |
SP-96 是一种高效的特异性 Aurora B 抑制剂,IC50 为 0.316 nM。 SP-96 在 NCI60 筛选中显示特异性生长抑制,如 MDA-MD-468 (GI50=107 nM)。 SP-96 可用于三阴性乳腺癌研究。 | |||
T9468 |
FR054
|
Others | Others |
FR054 是一种己糖胺生物合成途径酶 PGM3 的抑制剂,具有明显的抗乳腺癌活性。它在不同的乳腺癌细胞中诱导细胞增殖和存活显著降低。 | |||
T13780 |
MS1943
|
Apoptosis; Histone Methyltransferase | Apoptosis; Chromatin/Epigenetic |
MS1943 是一种具有口服生物活性的 EZH2选择性降解剂,IC50为 120 nM。它显著降低了许多三阴性乳腺癌和其他癌及非癌细胞系中的 EZH2蛋白水平,能有效阻止多个三阴性乳腺癌和其他癌细胞系的增殖。 | |||
T6797 |
Telaglenastat
CB 839,CB839,CB-839 |
transporter; Glutaminase; Autophagy | Autophagy; Metabolism; Proteases/Proteasome |
Telaglenastat (CB 839) 是一种选择性可逆的,有口服活性的谷氨酰胺酶 1 (GLS1) 抑制剂,抑制 GLS1剪接变异体 KGA 和 GAC,比 GLS2 具有更高的选择性。它可诱导细胞自噬 ,具有抗肿瘤活性。它对小鼠类肾和脑中的内源性谷氨酰胺酶的 IC50值分别为 23 nM 和 28 nM。 | |||
T13044 |
Mevociclib
SY-1365 |
CDK | Cell Cycle/Checkpoint |
Mevociclib (SY-1365) 是一种高效选择性 CDK7抑制剂,Ki 值为 17.4 nM。它具有抗血液肿瘤和侵袭性实体肿瘤作用,有抗增殖和凋亡活性。 | |||
T19664 |
ON1231320
GBO-006 |
Apoptosis; PLK | Apoptosis; Cell Cycle/Checkpoint |
ON1231320 (GBO-006) 是一种高度特异性的 polo 样激酶 2 抑制剂,IC50为 0.31 µM。在有丝分裂 G2/M 期阻断肿瘤细胞周期进程,它可导致细胞凋亡。它是一种芳基磺酰基吡啶并嘧啶酮,具有抗肿瘤活性。 | |||
T2655 |
CEP-37440
CEP37440 |
FAK; ALK | Angiogenesis; Cytoskeletal Signaling; Tyrosine Kinase/Adaptors |
CEP-37440 是一种新型的 FAK (IC50:2.3 nM) 和 ALK (IC50:120 nM) 双重抑制剂。 | |||
T9320 |
YK-3-237
B-[2-Methoxy-5-[(1E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propen-1-yl]phenyl]boronic acid |
Sirtuin | Chromatin/Epigenetic; DNA Damage/DNA Repair |
YK-3-237 (B-[2-Methoxy-5-[(1E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propen-1-yl]phenyl]boronic acid) 是 SIRT1 激活剂,靶向突变体 p53。它抑制三阴性乳腺癌细胞的增殖。 | |||
T8808L |
LYN-1604 dihydrochloride
LYN-1604 2HCl(2216753-86-3 free base) |
Apoptosis; Autophagy | Apoptosis; Autophagy |
LYN-1604 2HCl 是一种有效的 UNC-51 样激酶 1 激活剂,EC50值为 18.94 nM。LYN-1604 可研究三阴性乳腺癌。 | |||
T4123 |
LYN-1604
LYN1604 |
Apoptosis; Autophagy | Apoptosis; Autophagy |
LYN-1604 是一种新型 ULK1 激活剂,EC50值为 18.94 nM。它可诱导参与 ATF3、RAD21 和 caspase3 的细胞死亡,并伴有自噬和细胞凋亡,可研究三阴性乳腺癌。 | |||
T35528 |
TD52
|
Apoptosis; Phosphatase; Akt | Apoptosis; Cytoskeletal Signaling; Metabolism; PI3K/Akt/mTOR signaling |
TD52 是 PP2A (CIP2A) 癌性抑制剂的口服活性抑制剂。 TD52 是厄洛替尼衍生物,通过干扰 Elk1 与 CIP2A 启动子的结合间接降低了 CIP2A。 | |||
T70353 |
JG-231
|
HSP | Cytoskeletal Signaling; Metabolism |
JG-231 是 JG-98 类似物,具有抗癌活性。JG-231 对三阴性乳腺癌 (TNBC) 的 MDA-MB-231 异植肿瘤模型具有抑制作用。JG-231 可抑制 Hsp70-BAG3 的相互作用。JG-231 对三阴性乳腺癌 (TNBC) 的 MDA-MB-231 异植肿瘤模型具有抑制作用。 | |||
T6224 |
Iniparib
NSC-746045,IND-71677,3-硝基-4-碘苯甲酰胺,BSI-201 |
PARP; Influenza Virus | Chromatin/Epigenetic; DNA Damage/DNA Repair; Microbiology/Virology |
Iniparib (BSI-201) 是一种不可逆的 PARP1抑制剂,在三阴性乳腺 Y 中表现出效力。 | |||
T8569 |
DMH-25
|
mTOR | PI3K/Akt/mTOR signaling |
DMH-25 是一种新型共价有效的 mTOR 抑制剂,在体内对三阴性乳腺癌细胞具有抗肿瘤活性。 | |||
T74178 |
Glembatumumab vedotin
CR011-vcMMAE,CR 011 ADC,CDX-011 |
Microtubule Associated | Cytoskeletal Signaling |
Glembatumumab vedotin (CDX-011) 是一种抗体活性小分子偶联物,Glembatumumab vedotin 具有强大的抗癌作用,可用于研究三阴性乳腺癌(TNBC)。 | |||
T9583 |
HJ-PI01
N-Acetylphenoxazine,10-acetylphenoxazine |
Pim | Chromatin/Epigenetic; JAK/STAT signaling |
HJ-PI01 (HJ-PI01) 是一种 Pim-2 抑制剂。它在三阴性人乳腺癌中诱导细胞凋亡和自噬性细胞死亡。 | |||
T7296 |
THZ2
CDK7-IN-1 |
CDK | Cell Cycle/Checkpoint |
THZ2 (CDK7-IN-1) 是 THZ1 的类似物,是一种有效的选择性 CDK7 抑制剂 ,IC50值为 13.9 nM。它有治疗三阴性乳腺癌的潜力。 | |||
T72528 |
NSC243928 mesylate
|
HuR | Chromatin/Epigenetic |
NSC243928 mesylate 可与人类淋巴细胞抗原 6 (LY6) 结合,是细胞生长抑制剂,具有抗癌活性,以 LY6K 依赖性方式诱导三阴性乳腺癌细胞的细胞死亡。 | |||
T77759 |
GPX4-IN-6
|
GPX | oxidation-reduction |
GPX4-IN-6 是一种小分子共价 GPX4 抑制剂(IC50: 0.12 μM),具有抗肿瘤活性。GPX4-IN-6 可促使铁死亡,用于治疗=和预防三阴性乳腺癌 (TNBC)。 | |||
T77755 |
GPX4-IN-5
|
GPX | oxidation-reduction |
GPX4-IN-5 是一种小分子共价 GPX4 抑制剂(IC50: 0.12 μM),具有抗肿瘤活性。GPX4-IN-5 可促使铁死亡,可用于预防和治疗三阴性乳腺癌 (TNBC)。 | |||
T8325 |
SR-4835
|
Apoptosis; CDK | Apoptosis; Cell Cycle/Checkpoint |
SR-4835 是一种 ATP 竞争性的 CDK12/CDK13高选择性抑制剂。它与破坏 DNA 的化学疗法和 PARP 抑制剂协同作用,并引起三阴性乳腺癌细胞凋亡。 | |||
T14685 |
BMS-986158
|
Epigenetic Reader Domain | Chromatin/Epigenetic |
BMS-986158 是一种BET 抑制剂,在 MDA-MB231 三阴性乳腺癌细胞和 NCI-H211 小细胞肺癌细胞中,对 BET 的IC50分别为 5 和 6.6 nM。 | |||
T17206 |
UPGL00004
|
Others; Glutaminase | Others; Proteases/Proteasome |
UPGL00004 是一种有效的谷氨酰胺酶 C (GAC) 抑制剂 ,其 IC50为29 nM。UPGL00004 对 GAC 的 Kd 为27 nM。UPGL00004 对高度侵袭性三阴性乳腺癌细胞系的增殖具有很强的抑制作用 。 | |||
T35528L |
TD52 dihydrochloride
TD52 dihydrochloride(1798328-24-1 Free base),TD52 2HCl |
Others | Others |
TD52 dihydrochloride (TD52 2HCl), a derivative of Erlotinib, is a potent and orally active inhibitor of protein phosphatase 2A (CIP2A). It exhibits strong anti-cancer properties by regulating the CIP2A/PP2A/p-Akt signaling pathway, resulting in the induction of apoptosis in triple-negative breast cancer (TNBC) cells. Mechanistically, TD52 dihydrochloride disrupts the binding of Elk1 to the CIP2A promoter, effectively reducing CIP2A levels. Notably, TD52 dihydrochloride demonstrates powerful anti... | |||
T62077 |
VT103
VT-103,VT 103 |
YAP | Stem Cells |
VT103 是一种具有口服活性和选择性的 TEAD1 蛋白棕榈酰化抑制剂,是 VT101 的类似物。 VT103 有潜在的抗肿瘤活性,可抑制 YAP/TAZ-TEAD 促进的基因转录,阻断 TEAD auto-palmitoylation,阻断 YAP/TAZ和TEAD 之间的相互作用。VT103 可用于研究HER2阳性乳腺癌、前列腺癌和三阴性乳腺癌。 | |||
T11600 |
IBR2
Isoquinoline |
DNA/RNA Synthesis | Cell Cycle/Checkpoint; DNA Damage/DNA Repair |
IBR2(Isoquinoline)是一种针对RAD51的强效特异性抑制剂,通过干预RAD51多聚体形成,加速蛋白酶体介导的RAD51蛋白降解,抑制癌细胞生长并诱导凋亡。实验证明在抑制RAD51介导的DNA双链断裂修复方面有效。 | |||
T39687 |
LYN-1604 hydrochloride
|
||
LYN-1604 hydrochloride, a powerful activator of UNC-51-like kinase 1 (ULK1) with an EC50 value of 18.94 nM, has significant implications in the study of triple-negative breast cancer (TNBC). | |||
T40182 |
Ascochlorin A
Acremochlorin A |
||
Ascochlorin A is a novel and potent hDHODH inhibitor ( K D = 3.29 μM) for treatment of triple-negative breast cancer. | |||
T40310 |
PARP/EZH2-IN-1
PARP/EZH2-IN-1 |
||
PARP/EZH2-IN-1 is a novel compound that functions as a dual inhibitor for both PARP (IC50 6.87 nM) and EZH2 (IC50 36.51 nM), showing promising potential for the treatment of triple-negative breast cancer with wild-type BRCA. | |||
T39992 |
FGFR1 inhibitor-2
FGFR1 inhibitor-2 |
||
FGFR1 inhibitor-2 (with an IC50 of 4.55 μM in MDA-MB-231 cells) is a potent inhibitor of FGFR1. It is specifically useful for studying metastatic triple-negative breast cancer. | |||
T74219 |
Maximiscin
|
||
Maximiscin 是一种真菌代谢产物,可诱导DNA damage 损伤,并对一种三阴性乳腺癌亚型显示出选择性的细胞毒活性。 | |||
T72638 |
iNOS inhibitor-10
|
NO Synthase | Immunology/Inflammation |
iNOSinhibitor-10 (Compound 1b)作为iNOS抑制剂,显示出对三阴性乳腺癌细胞的抗增殖能力,其IC50值为65 nM。 | |||
T13889 |
SLLN-15
|
Others | Others |
SLLN-15 是一个具有口服活性的、选择性的、有效的自噬 (autophagy) 增强剂。SLLN-15 可激活三阴乳腺癌细胞的自噬。 | |||
T2092L |
Amitifadine free base
DOV 21947,DOV-21947,DOV21,947,DOV21947,DOV 21,947,DOV-21,947 |
||
Amitifadine(DOV-21947, EB-1010) is an inhibitor of the so-called triple reuptake or serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) and is an antidepressant drug candidate. Amitifadine reduces binge drinking and negative affect in an animal m | |||
T60749 |
Autophagy-IN-2
|
||
Autophagy-IN-2 (Compound 7h) 是自噬通量的抑制剂,可诱导癌细胞凋亡,具有研究三阴性乳腺的潜力。 | |||
T69437 |
NDJ18
|
||
NDJ18 is a potent and selective SIRT2 inhibitor which validated the in silico protocol and opened up the possibility for generalization and broadening of its application. The anticancer effects of the most potent compound NDJ18 were examined on the triple-negative breast cancer cell line. Results indicated that NDJ18 represents a promising structure suitable for further evaluation. | |||
T40891 |
ADTL-SA1215
ADTL-SA1215 |
||
ADTL-SA1215 is a novel, highly selective small-molecule compound that acts as a specific activator of SIRT3, a protein known to play a crucial role in modulating autophagy. This compound holds great potential in the treatment of triple-negative breast cancer, as it effectively targets the molecular pathways associated with this subtype of cancer. | |||
T80216 |
DOTA-CXCR4-L
|
CXCR | Autophagy; GPCR/G Protein; Immunology/Inflammation |
DOTA-CXCR4-L为针对CXCR4的靶向肽,适用于癌症研究,如胶质母细胞瘤和三阴性乳腺癌。 | |||
T64053 | Bcl-2-IN-8 | ||
Bcl-2-IN-8 是一种有效的抗癌剂。Bcl-2-IN-8 对药物敏感和耐药的癌细胞均表现出抗增殖效果。Bcl-2-IN-8 以剂量依赖性方式抑制细胞迁移。Bcl-2-IN-8 能够将细胞周期阻滞在 G1 期,并诱导细胞凋亡。Bcl-2-IN-8 对三阴乳腺癌表现出研究潜力。 | |||
T79604 |
SHR5428
|
CDK | Cell Cycle/Checkpoint |
SHR5428为口服选择性非共价CDK7抑制剂,显示出高效CDK7酶活性抑制(IC50=2.3 nM)。它还有效抑制MDA-MB-468细胞系中的三阴性乳腺癌细胞活性(IC50=6.6 nM)。 | |||
T72328 | Cyclopropenone probe 1 | ||
Cyclopropenone probe 1 可以通过在催化活性位点共价结合,特异且有效地修饰三阴性乳腺癌驱动因子 GSTP1。 | |||
T74675 |
MS8815
|
||
MS8815 是 zeste 同源物2(EZH2)PROTAC 降解剂,具有选择性。MS8815 对 EZH2有抑制活性,IC50值为 8.6 nM。MS8815 可用于三阴性乳腺癌 (TNBC) 研究。 | |||
T74802 | FAK-IN-9 | ||
FAK-IN-9 (Compound 8f) 是一种有效的和具有口服活性的FAK 抑制剂,其IC50为 27.44 nM。FAK-IN-9 诱导三阴性乳腺癌 (TNBC) 细胞凋亡(apoptosis)。 | |||
T73995 | EGFR/CSC-IN-1 | EGFR | Angiogenesis; JAK/STAT signaling; Tyrosine Kinase/Adaptors |
EGFR/CSC-IN-1为针对三阴性乳腺癌研究的潜在EGFR(IC50为10.52 nM)及肿瘤干细胞(CSC)双重抑制剂。 | |||
T79410 | anti-TNBC agent-3 | ||
Anti-TNBC agent-3 (compound 3g) 作为凋亡诱导剂,展现了抗增殖活性针对癌细胞。在三阴性乳腺癌(TNBC)异种移植模型上,该化合物有效地抑制了肿瘤生长及其转移。 | |||
T61582 |
Anticancer agent 57
|
||
Anticancer agent 57 (compound 14) demonstrates potent inhibition of MDA-MB-231, MDA-MB-468, and MCF-7 cell lines, with IC 50 values ranging from 6.43 to 8.00 μM. Additionally, this agent induces cell cycle arrest and promotes apoptosis. In vivo studies using nude mice xenografted with MADMB-231 cells have shown that Anticancer agent 57 effectively inhibits tumor growth. Consequently, Anticancer agent 57 can serve as a valuable tool for researching triple negative breast cancer (TNBC) [1]. | |||
T39815 | anti-TNBC agent-1 | ||
anti-TNBC agent-1 is a highly effective compound specifically designed to target and combat triple-negative breast cancer (TNBC). It demonstrates remarkable potency against various breast cancer cell types, with IC50 values spanning from 0.20 μM to 0.27 μM. The mechanism of action of anti-TNBC agent-1 involves inducing apoptosis in SUM-159 cells through the mitochondria pathway, as well as causing G1 phase arrest in these cells. | |||
T73501 |
MC0704
|
||
MC0704 是一种 STAT3抑制剂,IC50值为 2.13 μM。MC0704 诱导细胞凋亡和细胞周期阻滞。MC0704 在小鼠乳腺癌模型中显示出抗肿瘤活性。MC0704 可用于转移性三阴性乳腺癌 (mTNBC) 的研究。 | |||
T62540 | PARP1/BRD4-IN-2 | ||
PARP1/BRD4-IN-2 是一种有效的、选择性的 PARP1 (IC50: 197 nM) 和 BRD4 (IC50: 238 nM) 抑制剂。PARP1/BRD4-IN-2 能够抑制 DNA 损伤修复,阻滞 G0/G1 细胞周期转变,诱导细胞凋亡 (apoptosis)。PARP1/BRD4-IN-2 对 MDA-MB-468 小鼠异种移植瘤模型表现出抗肿瘤效果。PARP1/BRD4-IN-2 能够用于研究三阴性乳腺癌 (TNBC)。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T2896 |
Alantolactone
土木香内酯,helenin,Eupatal,Helenine,(+)-Alantolactone,Alant camphor,土木香脑,Inula camphor |
Apoptosis; STAT; TGF-beta/Smad | Apoptosis; JAK/STAT signaling; Stem Cells |
Alantolactone (Inula camphor) 是一种STAT3的选择性抑制剂,可诱导癌症相关的凋亡,具有抗肿瘤活性。 | |||
T7979 |
2-Hydroxychalcone
2-(2-Hydroxybenzal)Acetophenone,2-羟基查酮 |
Apoptosis; BCL; Others; NF-κB | Apoptosis; NF-κB; Others |
2-Hydroxychalcone (2-(2-Hydroxybenzal)Acetophenone) 是一种天然黄酮,可通过下调 Bcl-2 诱导凋亡,也可抑制NF-kB 的激活。它是抗氧化剂,抑制脂质过氧化,还可抑制三阴性乳腺癌细胞的侵袭。 | |||
T6S1683 |
Demethoxycurcumin
Curcumin II,去甲氧基姜黄素,Desmethoxycurcumin,脱甲氧姜黄,Monodemethoxycurcumin |
Apoptosis; Antioxidant; Antibacterial; Autophagy | Apoptosis; Autophagy; Microbiology/Virology; oxidation-reduction |
Demethoxycurcumin (Desmethoxycurcumin) 是姜黄素的主要活性成分,有抗炎和抗癌作用。 | |||
T21771 |
Pyoluteorin
|
Antibiotic | Microbiology/Virology |
Pyoluteorin 是一种抗生素 (antibiotic),可抑制 Oomycete fungi,包括植物病原体 Oomycete fungi,并抑制由该真菌引起的植物病害。 Pyoluteorin 在体外诱导人三阴性乳腺癌 MDA-MB-231 细胞凋亡 (apoptosis)。 Pyoluteorin 可用于人类三阴性乳腺癌的研究。 | |||
T3418 |
Demethylzeylasteral
去甲泽拉木醛,Demethylzeylasteral (T-96) |
Apoptosis; UGT | Apoptosis; Metabolism |
Demethylzeylasteral (Demethylzeylasteral (T-96)) 分离自雷公藤,具有抗炎、免疫抑制和抗肿瘤活性。它通过阻断 TGF-β 信号通路,抑制三阴性乳腺癌的侵袭,它能显著减轻动脉粥样硬化。 | |||
TN2691 |
2',3'-Dehydrosalannol
|
BCL; Akt; Caspase | Apoptosis; Cytoskeletal Signaling; PI3K/Akt/mTOR signaling; Proteases/Proteasome |
2',3'-Dehydrosalannol possesses antifeedant activity against Spodptera litura. It shows anticancer effects on triple-negative breast cancer(TNBC), it inhibits cathepsin-mediated pro-survival signaling which resulted in growth arrest of TNBC cells. |